The short version of Cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-09. Anything still debated is marked as such rather than presented as settled.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
=== Development === The main function of fibroblasts is to maintain the structural integrity of connective tissues by continuously secreting precursors of the extracellular matrix (ECM), providing all such components, primarily the ground substance and a variety of fibers. The composition of the ECM determines the physical properties of connective tissues. Like other cells of connective tissue, fibroblasts are derived from primitive mesenchyme. Hence, they express the intermediate filament protein vimentin, a feature used as a marker to distinguish their mesodermal origin. However, this test is not specific as epithelial cells cultured in vitro on adherent substratum may also express vimentin after some time. In certain situations, epithelial cells can give rise to fibroblasts, a process called epithelial-mesenchymal transition. Conversely, fibroblasts in some situations may give rise to epithelia by undergoing a mesenchymal to epithelial transition and organizing into a condensed, polarized, laterally connected true epithelial sheet. This process is seen in many developmental situations (e.g. nephron and notocord development), as well as in wound healing and tumorigenesis.
Collagen alpha-2(I) chain is a protein that in humans is encoded by the COL1A2 gene. This gene encodes one of the chains for type I collagen, the fibrillar collagen found in most connective tissues. Mutations in this gene are associated with osteogenesis imperfecta, Cardiac-valvular and Arthrochlasia type Ehlers–Danlos syndrome, idiopathic osteoporosis, and atypical Marfan syndrome. Symptoms associated with mutations in this gene, however, tend to be less severe than mutations in the gene for alpha-1 type I collagen, since alpha-2 is less abundant. Multiple messages for this gene result from multiple polyadenylation signals, a feature shared by most of the other collagen genes.
=== Video games === The term applies to video games that persuade consumers to buy a particular video game console or accessory, by virtue of platform exclusivity. Such a game is also called a "system seller".
== Method of action == Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
=== Russian involvement === It was noted by Newsweek in July 2024 that the Houthis were in possession of Russian-made P-800 Oniks missiles, and that the transfer had likely occurred via Syria and Iran. In July 2024, The Wall Street Journal reported that US officials saw increasing indications that Russia was considering arming the Houthis with advanced anti-ship missiles via Iranian smuggling routes in response to US support for Ukraine during Russia's invasion. However, it did not follow through due to pushback by the US and Saudi Arabia. In August 2024, Middle East Eye, citing a US official, reported that personnel of Russia's GRU were stationed in Houthi-controlled parts of Yemen to assist the militia's attacks on merchant ships. In October, The Wall Street Journal reported that Russia was supplying the Houthis with geospatial intelligence to target Western ships.
Sources: en.wikipedia.org
A growth factor is a naturally occurring substance capable of stimulating cell proliferation, wound healing, and occasionally cellular differentiation. Usually it is a secreted protein or a steroid hormone.
Everything the intelligentsia had ever hoped for in terms of freedom of expression and publication was suddenly available. Thanks to glasnost, the Soviet press was full of informed, detailed criticisms of historical ‘mistakes’ such as collectivization, the Great Purges, bad decisions in World War II, wartime ethnic deportations and postwar anti-Semitism. Newspapers and thick journals competed with each other for exposés, publishing all the manuscripts in drawers that had hitherto been forbidden and pushing for rehabilitation of fallen revolutionary heroes. It was a wonderful time to be a Soviet writer of a certain age and type—a Khrushchevian truth-teller whose realist novels and plays unmasked social ills, historical cover-ups and political scandals. It was an equally exciting time to be a Soviet reader, except that there was too much to read, and what one read was likely to shake one's faith in the Soviet system. Gorbachev's assumption, like that of the old reform-minded thick journals, was that 'telling the truth' could not but be good, ultimately strengthening the Soviet system by purifying it. Unfortunately, the opposite proved to be the case. The effect of the crash course on the flaws of Soviet socialism was to undermine the public’s confidence rather than rally it for reform. Additionally, the internal political reforms associated with perestroika altered both the political consciousness of Soviet society and the strategic outlook of Soviet foreign policy.
=== Proposals for housing affordability === In January 2026, Trump proposed several actions and policies to make housing more affordable. These included the banning of "large institutional investors" from buying single-family homes, buying up to $200 billion of mortgage debt in order to reduce mortgage interest rates [already started earlier in the month], making 50-year mortgages available, making portable mortgages available, and allowing homebuyers to use their 401(k)s plans for down payments. Critics say the housing shortage is the number one reason for higher prices and that addressing this shortage will take a number of state and local actions. Critics also say that making portable mortgages available would give existing homeowners an even bigger advantage over first-time buyers. In January 2026, Trump announced that he had ordered Fannie Mae and Freddie Mac to buy up to $200 billion in mortgage-backed bonds to drive down interest rates for new mortgages. The interest rates have since fallen.
== Treatment == Treatment for postinflammatory hyperpigmentation may include topical agents like hydroquinone, retinoids, ascorbic acid, and azelaic acid, as well as chemical peels or laser therapy to promote skin renewal and reduce pigmentation. Sun protection is also crucial to prevent further darkening of the affected skin. In severe or recurrent cases, combination therapy of hydroquinone plus one or more additional topical agents is common. Topical medications and other non-procedural treatments are preferred over chemical peels, laser therapy, dermabrasion, and other "destructive therapies". This is because the topical treatments are often very effective in managing PIH and typically cost less, while also having lower potential for side effects or worsening of the condition. Some patients (especially those with darker skin) have been known to experience worsening of their PIH with destructive therapy, rather than improvement. The reason for this is often not known.
The result would be a higher frequency of the allele responsible for the His-variant enzyme in regions that had been under selective pressure the longest. The distribution and frequency of the His variant follows the spread of rice cultivation to inland regions of Asia, with higher frequencies of the His variant in regions that have cultivated rice the longest. The geographic distribution of the alleles seems to therefore be a result of natural selection against individuals with lower reproductive success, namely, those who carried the Arg variant allele and were more susceptible to alcoholism. However, the persistence of the Arg variant in other populations argues that the effect could not be strong.
Sources: en.wikipedia.org
=== Angevin transition === After the Polish royal line and Piast junior branch died out in 1370, Poland came under the rule of Louis I of Hungary of the Capetian House of Anjou, who presided over a union of Hungary and Poland that lasted until 1382. In 1374, Louis granted the Polish nobility the Privilege of Koszyce to assure the succession of one of his daughters in Poland. His youngest daughter Jadwiga (d. 1399) assumed the Polish throne in 1384.
At first glance, this result would seem to contradict the assertion that states choose alliance partners in order to balance against the strongest. Focusing solely on aggregate power would lead us to expect more states to ally with the Soviet Union, in order to prevent the United States from using its superior overall resources in harmful ways. Judging from the preponderance of aggregate power favoring the West, many states appear to have 'bandwagoned' rather than balanced by aligning with the United States. This is even more striking when one remembers that the United States was overwhelmingly the world's most powerful country in the immediate postwar period, yet was able to bring most of the other industrial powers into alignment with rather than against it. In 1986, still not envisaging the end of the Cold War in sight, Zbigniew Brzezinski emphasized the historical uniqueness of the current period regarding the preponderance of power: "[N]ever before would the eclipse of one of the major rival powers have given to the other effective global preponderance." Shortly after one of the rival superpowers eclipsed, the Pentagon Regional Defense Strategy (1992) formulized: "It is not in our interest … to return to earlier periods in which multiple military powers balanced one against another in what passed for security structures, while regional or even global peace hang in the balance." In the first post-Cold War year, Leffler advocated for the United States to continue its strategy of "preponderance of power".
ICV injection of α-Interferon has been used for the treatment of intracranial malignancies in the clinic. α-Interferon has antiviral, antibacterial, and immunostimulatory properties. However, severe central nervous system symptoms occur after injection for ICV, intravenous, and intramuscular routes of administration. Additionally, only .09-.18% of the total Interferon dose was seen to pass through the blood-brain barrier when injected intramuscularly. In one study, intraperitoneal injection of α-Interferon was done on mice and there was no impact on monoamine levels. Another study conducted a similar experiment using the ICV injection method. This study showed reduced monoamine levels in the frontal cortex, in a dose-dependent manner. This indicates that ICV injection increases the percentage of the dose that reaches the mouse brain.
These "de facto experiments investigating the physiology of stress as well as the substances that might alleviate exhaustion" were not unknown outside cycling. Thomas Hicks, an American born in England on 7 January 1875, won the Olympic marathon in 1904. He crossed the line behind a fellow American Fred Lorz, who had been transported for 11 miles of the course by his trainer, leading to his disqualification. However, Hicks's trainer Charles Lucas, pulled out a syringe and came to his aid as his runner began to struggle.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.